113 related articles for article (PubMed ID: 38099238)
1. RE: Incidence of SARS-CoV-2 Breakthrough Infections After Vaccination in Adults: A Population-Based Survey Through 1 March 2023.
DeSantis SM; Yaseen A; Hao T; León-Novelo L; Talebi Y; Valerio-Shewmaker MA; Pinzon Gomez CL; Messiah SE; Kohl HW; Kelder SH; Ross JA; Padilla LN; Silberman M; Wylie S; Lakey D; Shuford JA; Pont SJ; Boerwinkle E; Swartz MD
Open Forum Infect Dis; 2023 Dec; 10(12):ofad564. PubMed ID: 38099238
[No Abstract] [Full Text] [Related]
2. Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants.
DeSantis SM; Yaseen A; Hao T; León-Novelo L; Talebi Y; Valerio-Shewmaker MA; Pinzon Gomez CL; Messiah SE; Kohl HW; Kelder SH; Ross JA; Padilla LN; Silberman M; Tuzo S; Lakey D; Shuford JA; Pont SJ; Boerwinkle E; Swartz MD
J Infect Dis; 2023 May; 227(10):1164-1172. PubMed ID: 36729177
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
[TBL] [Abstract][Full Text] [Related]
4. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J; Matthews PC; Stoesser N; Newton JN; Diamond I; Studley R; Taylor N; Bell JI; Farrar J; Kolenchery J; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
Nat Commun; 2023 May; 14(1):2799. PubMed ID: 37193713
[TBL] [Abstract][Full Text] [Related]
5. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
6. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
7. Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults.
Nishimi K; Neylan TC; Bertenthal D; Seal KH; O'Donovan A
JAMA Netw Open; 2022 Apr; 5(4):e227287. PubMed ID: 35420660
[TBL] [Abstract][Full Text] [Related]
8. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
10. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
11. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021.
Teran RA; Walblay KA; Shane EL; Xydis S; Gretsch S; Gagner A; Samala U; Choi H; Zelinski C; Black SR
MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(17):632-638. PubMed ID: 33914721
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
13. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
14. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Moscara L; Venerito V; Martinelli A; Di Lorenzo A; Toro F; Violante F; Tafuri S; Stefanizzi P
Vaccine; 2023 Aug; 41(38):5655-5661. PubMed ID: 37544827
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
[TBL] [Abstract][Full Text] [Related]
16. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
Torres I; Bellido-Blasco JB; Gimeno C; Burgos JS; Albert E; Moya-Malo R; Gascó-Laborda JC; Tornero A; Soriano J; Meseguer-Ferrer N; Martínez-Serrano M; Ortíz-Rambla J; Buj H; Hernández N; Peiró S; Salas D; Limón R; Vanaclocha H; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Navarro D;
J Med Virol; 2022 Aug; 94(8):3776-3782. PubMed ID: 35445415
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.
Karimi M; Zarei T; Haghpanah S; Azarkeivan A; Naderi M; Matin S; Bazrafshan A; Zahedi Z; Shirkavand A; Pishdad P; De Sanctis V
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022026. PubMed ID: 35444764
[TBL] [Abstract][Full Text] [Related]
20. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern.
Ruhl L; Kühne JF; Beushausen K; Keil J; Christoph S; Sauer J; Falk CS
Front Immunol; 2023; 14():1120010. PubMed ID: 37033958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
